Key result
Evolocumab lowers LDL-C and affects clinical outcomes in peripheral artery disease.
Key points are not available for this paper at this time.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Evidence from randomized controlled trials confirms that intensified lipid lowering reduces MALE and major adverse cardiovascular events (MACE), reinforcing lipid management as a core limb-preserving strategy in PAD.”
Supports intensified lipid lowering for limb preservation in peripheral artery disease; leaves open whether evolocumab confers outcome benefits beyond LDL reduction.
URL: https://www.clinicaltrials.gov. Unique identifier: NCT01764633.
No takes yet. Share an insight, caveat, or question.
Bonaca et al. (2017) studied this question. Evolocumab lowers low-density lipoprotein cholesterol and affects clinical outcomes in patients with peripheral artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: